HEPAVAC

Cancer Vaccine development for Hepatocellular Carcinoma

 Coordinatore ISTITUTO NAZIONALE TUMORI Fondazione Pascale 

 Organization address address: Via Mariano Semmola 142
city: NAPOLI
postcode: 80131

contact info
Titolo: Dr.
Nome: Vincenza
Cognome: Farinari
Email: send email
Telefono: 390816000000

 Nazionalità Coordinatore Italy [IT]
 Sito del progetto http://www.hepavac.eu
 Totale costo 8˙200˙536 €
 EC contributo 5˙996˙110 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-09-01   -   2018-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    ISTITUTO NAZIONALE TUMORI Fondazione Pascale

 Organization address address: Via Mariano Semmola 142
city: NAPOLI
postcode: 80131

contact info
Titolo: Dr.
Nome: Vincenza
Cognome: Farinari
Email: send email
Telefono: 390816000000

IT (NAPOLI) coordinator 1˙845˙500.00
2    IMMATICS BIOTECHNOLOGIES GMBH

 Organization address address: PAUL EHRLICH STR 15
city: TUEBINGEN
postcode: 72076

contact info
Nome: Maria
Cognome: Poulada
Email: send email
Telefono: +49 7071 5397 710
Fax: +49 7071 5397 900

DE (TUEBINGEN) participant 1˙934˙200.00
3    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Prof.
Nome: Hans-Georg
Cognome: Rammensee
Email: send email
Telefono: +49 7071 29 87628
Fax: +49 7071 29 5653

DE (TUEBINGEN) participant 700˙840.00
4    UNIVERSITA DEGLI STUDI DELL'INSUBRIA

 Organization address address: Via Ravasi 2
city: VARESE
postcode: 21100

contact info
Titolo: Prof.
Nome: Roberto
Cognome: Accolla
Email: send email
Telefono: +39 0332217606
Fax: +39 0332217608

IT (VARESE) participant 410˙796.80
5    CUREVAC GMBH

 Organization address address: PAUL EHRLICH STRASSE 15
city: TUEBINGEN
postcode: 72076

contact info
Titolo: Dr.
Nome: Oliver
Cognome: Schlüter
Email: send email
Telefono: 4970720000000

DE (TUEBINGEN) participant 312˙540.00
6    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Prof.
Nome: Danila
Cognome: Valmori
Email: send email
Telefono: +33 2 40 67 97 26
Fax: +332 40 67 97 63

FR (PARIS) participant 303˙520.00
7    THE UNIVERSITY OF BIRMINGHAM

 Organization address address: Edgbaston
city: BIRMINGHAM
postcode: B15 2TT

contact info
Titolo: Ms.
Nome: May
Cognome: Chung
Email: send email
Telefono: 441214000000
Fax: 441214000000

UK (BIRMINGHAM) participant 254˙914.00
8    UNIVERSIDAD DE NAVARRA

 Organization address address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL
city: PAMPLONA
postcode: 31080

contact info
Titolo: Mr.
Nome: Fco. Javier
Cognome: Irigoyen Barrio
Email: send email
Telefono: 34948176748
Fax: 34948175223

ES (PAMPLONA) participant 117˙950.00
9    UNIVERSITAIR ZIEKENHUIS ANTWERPEN

 Organization address address: WILRIJKSTRAAT 10
city: EDEGEM
postcode: 2650

contact info
Titolo: Prof.
Nome: Sven
Cognome: Francque
Email: send email
Telefono: +32 38214572
Fax: +32 3 8214478

BE (EDEGEM) participant 115˙850.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

taa    primary    epitope    cell    clinical    cd    tumor    endpoints    cancer    strategy    hepavac    prime    hla    vaccine    ligandome    schedule    responses    ablation    patients    epitopes    hcc    cocktail    boost   

 Obiettivo del progetto (Objective)

'Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for about 6% of all new cancer cases worldwide. Given the lack of available effective treatments, the overall prognosis for HCC patients is poor, with a dismal 5-year survival of 5-6%. The main goal of this proposal is to develop a therapeutic cancer vaccine aiming at improving clinical outcome in early-stage HCC patients after loco-regional ablative therapy. HepaVac is an European consortium of academic, SME and pharmaceutical company partners with complementary and substantial expertise in cancer immunotherapy and vaccine development. The main objective of HepaVac is to develop a novel cancer vaccine approach for HCC based on epitopes naturally processed and presented by HLA class I and II (HLA-ligandome), to elicit both CD4 T helper and CD8 CTL tumor-specific effector and memory responses. The HCC HLA-ligandome will be identified in primary tumor tissues using a combined and integrated approach, developed and thoroughly validated by Partners #2 and #5. The selected peptide epitopes will constitute the candidate cancer vaccine for HCC, aiming at covering the broadest haplotype diversity with a multi-epitope and multi-TAA strategy. T cell epitopes derived from universal TAA and unique patient-specific mutated antigens will allow the design of a prime-boost vaccine strategy based either on a prime-boost schedule made of an “off-the-shelf” T cell epitope cocktail or on a schedule where the boost is complemented by a “personalized” T cell epitope cocktail. Both epitope cocktails will be adjuvanted in a novel and potent immunomodulator developed by Partner #6. Such a vaccination strategy will be tested in a randomized controlled multi-center phase I/II human clinical trial, assessing as primary endpoints safety and induction of specific cellular immune responses and, as secondary endpoints, OS and PFS of patients receiving the vaccine after tumor ablation vs tumor ablation alone.'

Altri progetti dello stesso programma (FP7-HEALTH)

LUPA (2008)

Unravelling the molecular basis of common complex human disorders using the dog as a model system

Read More  

MARK-AGE (2008)

European Study to Establish Biomarkers of Human Ageing

Read More  

OPTIMUNISE (2011)

Optimising the impact and cost-effectiveness of child health intervention programmes of vaccines and micronutrients in low-income countries

Read More